LINC01474: A Long Intergenic Non-Protein Coding RNA and Potential Drug Target

Target Name: LINC01474

NCBI ID: G101927258

LINC01474

Other Name(s): Long intergenic non-protein coding RNA 1474, transcript variant 1 | long intergenic non-protein coding RNA 1474

LINC01474: A Long Intergenic Non-Protein Coding RNA and Potential Drug Target

LINC01474 is a long non-protein-coding RNA (lncRNA) that was identified using transcriptome sequencing (RNA-seq) data. It has a unique feature of being located between the coding regions of two adjacent genes, which leads to its name. LINC01474 is a non-coding RNA that is expressed in various cell types of the human body, including the brain, heart, and testes. The function of LINC01474 is not well understood, but its expression has been associated with various cellular processes, including cell adhesion, migration, and survival.

Drug Target Potential

The drug targeting potential of LINC01474 is an attractive topic of interest due to its unique expression pattern and the involvement of several cellular processes. LINC01474 has been shown to be involved in cell-cell adhesion, which is a critical process for tissue repair and regeneration. Additionally, LINC01474 has been associated with the regulation of cell migration and the establishment of tissue microstructure during development and wound healing.

Furthermore, LINC01474 has been shown to play a role in the regulation of cellular processes that are important for cancer progression, such as the regulation of apoptosis, cell cycle progression, and angiogenesis. Therefore, LINC01474 may be a potential drug target for cancer therapy.

Expression and Localization

LINC01474 is a long non-protein-coding RNA that is expressed in various cell types of the human body. It has been shown to be expressed in the brain, heart, and testes, among other tissues. LINC01474 is a novel lncRNA that has not been previously reported in the literature.

Function and Interaction

The function of LINC01474 is not well understood, but its expression is associated with several cellular processes. LINC01474 has been shown to be involved in cell-cell adhesion, which is a critical process for tissue repair and regeneration. Additionally, LINC01474 has been associated with the regulation of cell migration and the establishment of tissue microstructure during development and wound healing.

Furthermore, LINC01474 has been shown to play a role in the regulation of cellular processes that are important for cancer progression, such as the regulation of apoptosis, cell cycle progression, and angiogenesis. Therefore, LINC01474 may be a potential drug target for cancer therapy.

Conclusion

In conclusion, LINC01474 is a long non-protein-coding RNA that is expressed in various cell types of the human body. Its unique feature is its location between the coding regions of two adjacent genes, which makes it a novel and interesting molecule. The function of LINC01474 is not well understood, but its expression is associated with several cellular processes that are important for tissue repair, regeneration, and cancer progression. Therefore, LINC01474 may be a potential drug target for cancer therapy. Further studies are needed to determine the function of LINC01474 and its potential as a drug target.

Protein Name: Long Intergenic Non-protein Coding RNA 1474

The "LINC01474 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01474 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets